Medicaid concept
Adobe
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

Nanocap health software company HeraMED (ASX:HMD) has been slammed on Monday as the company revealed its US based health clinic partner will no longer use HeraMED’s ‘HeraCARE’ software package.

The company blamed changes in the American Medicaid system under Trump for hurting its bottom line.

“Post Trump administration taking office, the changing healthcare and health funding landscape has particularly impacted US health systems serving Medicaid populations,” HeraMED wrote on Monday.

One is left to note the company has done what many companies are too fearful to do at this time – directly link Trump to lost revenues.

At any rate, the US medicaid program is an NDIS-style welfare program for low-earners and disabled individuals. Hospitals receive funding under the program.

Broward Health, a ‘safety net’ medical clinic was effectively trialling HeraMED’s software in a non-clinical setting.

But a key grant which apparently enabled that program has now been cut as HeraMED highlighted that: “the average annual cut to the Medicaid budget is anticipated to be approximately $70 billion per annum, more than ten times larger than any previous annual cut made to the program.”

This is bad news for HeraMED, which has been seeking to tap into those funds by way of offering eligible products.

But what does HeraMED offer?

Its HeraCARE software supports another device called ‘HeraBEAT’ which can monitor a baby’s heartbeat; but overall, its product is effectively a biometrics software package.

“Despite positive maternal-fetal outcomes,” according to HeraMED, Broward has had to ditch the HeraCARE software. That wipes around US$100K (A$155K) of predicted revenue from the books for HeraMED.

“The agreement with Broward Health had estimated revenue in 2025 of USD$100,000 and served as an important Case Study,” the company wrote.

“Broward continued to report significant improvements to the maternal-fetal outcomes as recently as March 2025, highlighting that the decision is not related to the clinical performance or efficacy of the HeraCARE platform.”

As for what the company will do from here?

If CEO Anoushka Gungadin’s commentary was anything to go by, the company hasn’t quite figured out where yet: “We will continue to sharpen our focus where the need is urgent and the sales cycle shortest,” he wrote.

HMD last traded at 1.1cps.

Join the discussion: See what’s trending right now on HotCopper, Australia’s largest stock forum, and be part of the conversations that move the markets.

HMD by the numbers
More From The Market Online
The Market Online Video

West Coast Silver learning from Morocco secrets to ‘unlock’ Elizabeth Hill silver trove

Explorer West Coast Silver (ASX:WCE), formerly Errawarra Resources, is peeling back the layers of understanding at its Elizabeth Hill
The words "Market Open ASX 200 Futures Tip FALL" appear stacked atop one another next to ASX company iconography.

ASX Market Open: Sell-off as Musk-Trump spat overshadows Xi Jinping call | June 6, 2025

The Australian market looks set to continue its trickling down slide through to the closing bell in Week 23, with Thursday’s red close
The Market Online Video

ASX Market Close: ASX200 finishes close to open as profit takers descend

Good Afternoon and welcome to HotCopper Market Close for Thursday 5th of June 2025, I’m Jon…
The Market Online Video

Lithium Plus indentifies critical minerals potential at Arunta lithium projects

Lithium Plus Minerals (ASX:LPM) has landed a “significant discovery” at its Spotted Wonder project in the Northern Territory, uncovering